Brixton Biosciences Establishes Key Leadership for Scientific Advisory Board to Enhance Pain Therapy Development

Brixton Biosciences Appoints Co-Chairs for Scientific Advisory Board

Brixton Biosciences, a pioneering clinical-stage life sciences firm, has heralded an important milestone by announcing the appointment of two distinguished medical professionals, William J. Hozack, MD, and Brian J. Cole, MD, as Co-Chairs for its Scientific Advisory Board (SAB) on October 21, 2025. The duo is set to lead efforts to develop innovative therapies for both chronic and acute pain, particularly focusing on musculoskeletal conditions.

With their extensive backgrounds in total joint replacement and sports medicine, Dr. Hozack and Dr. Cole are strategically positioned to guide Brixton through the complexities of clinical development, aiming to deliver effective, drug-free solutions that tackle pain associated with osteoarthritis, post-surgical recovery, and various other conditions.

Expertise of New Leaders

Dr. William J. Hozack stands as the Walter Annenberg Professor of Joint Replacement Surgery at Thomas Jefferson University, having garnered immense respect in the field as a former President of the American Association of Hip and Knee Surgeons (AAHKS). His renowned reputation not just in surgery, but also as an educator, marks him as a vital asset for Brixton. Dr. Hozack stated, "Brixton Biosciences is addressing one of the most urgent challenges in healthcare with fresh thinking and rigorous science. I look forward to working alongside the team to help advance therapies that can significantly improve the quality of life for patients worldwide."

On the other hand, Dr. Brian J. Cole, currently the Acting Chair and Professor in the Department of Orthopedics at Rush University Medical Center, has an extensive portfolio of over 1,000 published works and contributions to 20 textbooks. His global reach in delivering lectures has made him one of the most cited orthopedic researchers. Dr. Cole expressed, "The work we are doing represents a meaningful advance in addressing chronic and post-surgical pain. Brixton Biosciences' innovative approach is not just an incremental step, but has the potential to fundamentally change how we deliver safer, more effective therapies for patients."

Advancements in Pain Management

The addition of Dr. Hozack and Dr. Cole to Brixton's leadership team signifies a commitment to accelerating the development of the company’s flagship treatment, ReneuRx™, previously known as Neural Ice. This innovative drug-free injectable therapy is focused on providing localized relief without the addictive properties found in many traditional pain medications. Brixton's strategy is to address the significant gaps in the current pain management landscape that has been widely dominated by systemic medications.

CEO Sameer Sabir remarked on the significance of this development: "The appointment of leadership to our Scientific Advisory Board marks an important milestone for Brixton Biosciences as we enter our next stage of growth. We are honored to collaborate with such distinguished pioneers in the field of orthopedics, whose insights will be invaluable in shaping our commitment to deliver innovative, drug-free solutions that transform the way pain is treated."

Recent Momentum and Future Directions

This announcement comes in conjunction with other recent achievements by Brixton Biosciences, including securing the Breakthrough Device Designation from the U.S. FDA, completing a robust $33 million Series B financing, and obtaining an NIH HEAL Grant to further its clinical initiatives. With an ongoing pivotal clinical study aimed specifically at knee osteoarthritis, the company is clearly on a trajectory of growth and innovation.

In summary, Brixton Biosciences is setting the stage for a meaningful shift in the management of chronic pain with innovative therapies guided by industry experts. As they continue to develop solutions rooted in scientific rigor, patients suffering from pain may soon have access to safer, more effective treatments that prioritize their well-being without the risks associated with traditional medications.